[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 317
1. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller R, Nathan M, Coleman N: Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2855-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.
  • PURPOSE: Early detection of anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) by screening will improve clinical outcome.
  • Assessment of anal cytology samples using routine Papanicolaou testing suffers from shortcomings in sensitivity and/or specificity, suggesting that screening tests based on biomarkers may be of value.
  • EXPERIMENTAL DESIGN: We undertook an initial immunohistochemical study of 54 anal tissue samples and validated our findings using an independent prospective cohort study of 235 anal cytology samples from 144 subjects.
  • RESULTS: In the progression from normal anal epithelium through AIN to SCC, there was increasing expression of MCM2 and MCM5, including in the superficial epithelial third, the source of the majority of cells collected by anal swab.
  • By immunocytochemistry using a mixture of anti-MCM2 and anti-MCM5 antibodies, immunopositive cells were readily identified in anal cytology samples, even at low magnification.
  • CONCLUSIONS: MCMs are promising biomarkers for improving detection of AIN and SCC in anal cytology samples.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U105359875; United Kingdom / Medical Research Council / / MRC/ MC/ U105359878; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


2. Marin-Muller C, Li M, Chen C, Yao Q: Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA). World J Surg; 2009 Apr;33(4):653-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).
  • Squamous cell carcinoma of the anus (SCCA) is a rare disease in the average population but is an increasing concern among immunocompromised individuals, such as the HIV-seropositive.
  • HPV infection is difficult to clear with a compromised immune system, which results in a greater risk of tumor development and a more aggressive progression of the disease.
  • The recent approval of a prophylactic HPV vaccine for cervical cancer has sparked an interest in a search for improved immunotherapeutic multimodality therapies to combat anogenital tumors associated with the virus.
  • In this review, we discuss the known mechanisms of action of HIV-associated SCCA, examine the current treatments for the disease, and focus on the potential of an immunotherapeutic vaccine approach for both prophylactic and therapeutic application.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sao Paulo Med J. 2007 Sep 6;125(5):292-4 [18094898.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] J Med Virol. 2008 Mar;80(3):478-83 [18205217.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] Virology. 2008 Mar 1;372(1):157-64 [18036631.001]
  • [Cites] BMC Cancer. 2008;8:8 [18194582.001]
  • [Cites] Pancreatology. 2008;8(2):110-25 [18382097.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1405-10 [18505087.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Mayo Clin Proc. 2008 Jun;83(6):701-6; quiz 706-7 [18533087.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1130-6 [18481150.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6544-9 [16166431.001]
  • [Cites] J Gen Virol. 2005 Oct;86(Pt 10):2709-20 [16186224.001]
  • [Cites] Am J Surg. 2005 Nov;190(5):732-5 [16226949.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1071-6 [16331617.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):189-206; quiz 207-10 [16443048.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):2880-93 [16472545.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] Cancer Gene Ther. 2006 Jun;13(6):592-7 [16456551.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1262-7 [16835321.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/106-13 [16949996.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4516-7 [16983122.001]
  • [Cites] Acta Dermatovenerol Croat. 2006;14(3):208 [17010274.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1581-6 [16977374.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11120-4 [17145854.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):100-8 [17066231.001]
  • [Cites] J Gen Virol. 2000 Mar;81(Pt 3):701-8 [10675407.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):397-404 [11332154.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Feb;26(2):150-6 [11938066.001]
  • [Cites] J Infect Dis. 2002 May 1;185(9):1229-37 [12001039.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1028-37 [12006515.001]
  • [Cites] Oncologist. 2002;7(3):188-99 [12065790.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2862-9 [12231528.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1561-9 [15238774.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):619-22 [15389001.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] J Surg Oncol. 1993 Jan;52(1):42-5 [8441261.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] J Virol. 1994 May;68(5):2811-21 [8151752.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] Cancer Gene Ther. 1995 Mar;2(1):19-32 [7621252.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1067-71 [8822106.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Ugeskr Laeger. 1998 Nov 30;160(49):7109-17 [9850615.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1024-30; discussion 1031 [15585390.001]
  • [Cites] Am Surg. 2004 Nov;70(11):1014-8 [15586518.001]
  • [Cites] AIDS Read. 2005 Feb;15(2):79-82, 85-6, 88, 91 [15712398.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Enferm Infecc Microbiol Clin. 2006 Nov;24 Suppl 2:40-6 [17194382.001]
  • [Cites] APMIS. 2007 Mar;115(3):195-203 [17367464.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):11-7 [17224640.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] JAMA. 2007 Aug 15;298(7):743-53 [17699008.001]
  • [Cites] Rev Assoc Med Bras. 2007 Jul-Aug;53(4):365-9 [17823743.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2780-9 [17638059.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1410-5; discussion 1415-6 [17710507.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2794-800 [17721997.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1744-51 [17846856.001]
  • [Cites] J Infect Dis. 2007 Nov 15;196(10):1438-46 [18008221.001]
  • (PMID = 19052810.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA132572-01; United States / NCI NIH HHS / CA / R13 CA132572; United States / NCI NIH HHS / CA / R13 CA132572-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / E6 protein, Human papillomavirus type 16; 0 / E6 protein, Human papillomavirus type 18; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus Vaccines; 0 / Repressor Proteins
  • [Number-of-references] 86
  • [Other-IDs] NLM/ NIHMS227649; NLM/ PMC2924142
  •  go-up   go-down


3. Ramamoorthy S, Luo L, Luo E, Carethers JM: Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev; 2008;32(2):116-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and risk of recurrence for squamous cell cancer of the anus.
  • OBJECTIVE: Squamous cell cancer of the anus is associated with multiple risk factors, including infection with human papillomavirus, immunosuppression, chronic inflammation, and tobacco smoking, although there is little data on these factors for the prediction of recurrent disease.
  • Here, we evaluated the risk of recurrence and mortality of anal carcinoma in association with tobacco smoking.
  • METHODS: We conducted a retrospective review of cases of anal carcinoma from two local hospitals.
  • RESULTS: We identified 64 patients with squamous cell cancer of the anus, and 34 of these (53%) had a tobacco smoking history.
  • CONCLUSION: Tobacco smoking appears to be associated with anal carcinoma disease recurrence, and is related to increased mortality.
  • This data suggests that patients should be cautioned about tobacco smoking once a diagnosis of anal carcinoma is made in attempt to improve their long-term outcome.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Anesth Analg. 1986 Nov;65(11):1186-8 [3767017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Prev Med. 1995 Jul-Aug;11(4):245-50 [7495601.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):853-8 [16815535.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):808-12 [11017836.001]
  • (PMID = 18639388.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NIDDK NIH HHS / DK / DK067287-01A2; United States / NIDDK NIH HHS / DK / R24 DK080506-01; United States / NIDDK NIH HHS / DK / R01 DK067287-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS209533; NLM/ PMC3427794
  •  go-up   go-down


Advertisement
4. Guasch G, Schober M, Pasolli HA, Conn EB, Polak L, Fuchs E: Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell; 2007 Oct;12(4):313-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.
  • Although TGFbeta is a potent inhibitor of proliferation, epithelia lacking the essential receptor (TbetaRII) for TGFbeta signaling display normal tissue homeostasis.
  • By studying asymptomatic TbetaRII-deficient stratified epithelia, we show that tissue homeostasis is maintained by balancing hyperproliferation with elevated apoptosis.
  • Moreover, rectal and genital epithelia, which are naturally proliferative, develop spontaneous squamous cell carcinomas with age when TbetaRII is absent.
  • This progression is associated with a reduction in apoptosis and can be accelerated in phenotypically normal epidermis by oncogenic mutations in Ras.
  • We show that TbetaRII deficiency leads to enhanced keratinocyte motility and integrin-FAK-Src signaling.
  • Together, these mechanisms provide a molecular framework to account for many of the characteristics of TbetaRII-deficient invasive SQCCs.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):260-6 [10559937.001]
  • [Cites] Cell. 1990 Jun 1;61(5):777-85 [2140528.001]
  • [Cites] J Invest Dermatol. 2000 Jul;115(1):3-11 [10886500.001]
  • [Cites] Wound Repair Regen. 2000 May-Jun;8(3):179-91 [10886809.001]
  • [Cites] Oncogene. 2000 Jul 27;19(32):3623-31 [10951568.001]
  • [Cites] Mol Biol Cell. 2001 Jan;12(1):27-36 [11160820.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5248-54 [11431366.001]
  • [Cites] Dev Biol. 2001 Aug 1;236(1):181-94 [11456453.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7435-43 [11606377.001]
  • [Cites] J Cell Sci. 2002 May 15;115(Pt 10):2189-98 [11973359.001]
  • [Cites] Cell. 1990 Aug 24;62(4):697-708 [1696852.001]
  • [Cites] Genes Dev. 1995 Apr 15;9(8):945-55 [7774812.001]
  • [Cites] Genes Dev. 1995 Aug 1;9(15):1831-45 [7649471.001]
  • [Cites] Prog Clin Biol Res. 1995;391:39-48 [8532731.001]
  • [Cites] Cell. 1996 Feb 9;84(3):359-69 [8608589.001]
  • [Cites] Cell. 1996 Aug 23;86(4):531-42 [8752208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):219-26 [8990189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2386-91 [9122204.001]
  • [Cites] Nature. 1997 May 22;387(6631):417-22 [9163429.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):25-34 [9671311.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Curr Biol. 1998 Nov 19;8(23):1243-52 [9822576.001]
  • [Cites] Cell. 1999 Feb 5;96(3):319-28 [10025398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8483-8 [10411901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8551-6 [10411913.001]
  • [Cites] Genes Dev. 2004 Dec 15;18(24):2998-3003 [15601818.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):339-47 [15668738.001]
  • [Cites] Science. 2005 Mar 11;307(5715):1603-9 [15761148.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2296-302 [15781643.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4703-15 [15899872.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1714-23 [15937546.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1331-42 [16702406.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2811-20 [16678165.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3272-9 [16740747.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9250-5 [16754864.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):506-20 [16794634.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5969-84 [16682956.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9837-44 [17047044.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3147-60 [17114585.001]
  • [Cites] J Cell Biol. 2007 Feb 26;176(5):667-80 [17325207.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:69-92 [17474876.001]
  • [Cites] Blood. 2002 Jul 15;100(2):560-8 [12091349.001]
  • [Cites] J Invest Dermatol. 2003 Aug;121(2):219-30 [12880412.001]
  • [Cites] Science. 2004 Jan 16;303(5656):359-63 [14671312.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):411-7 [15024388.001]
  • [Cites] J Cell Biol. 2004 Jun 7;165(5):723-34 [15184403.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4687-92 [15256431.001]
  • [Cites] Nature. 1984 Feb 16-22;307(5952):658-60 [6694757.001]
  • [Cites] J Cell Biol. 1984 Apr;98(4):1397-406 [6201492.001]
  • [Cites] Carcinogenesis. 1987 Dec;8(12):1821-5 [2824083.001]
  • [CommentIn] Cancer Cell. 2007 Oct;12(4):293-5 [17936552.001]
  • (PMID = 17936557.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR027883; None / None / / R01 AR027883-28; United States / NIAMS NIH HHS / AR / R01 AR027883-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrins; 0 / KRT14 protein, human; 0 / Keratin-14; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS44885; NLM/ PMC2424201
  •  go-up   go-down


5. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • However, the treatment response was graded as progressive disease, and the treatment was changed from CDDP to mitomycin C (MMC).
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


6. Mistrangelo M, Mobiglia A, Bellò M, Beltramo G, Cassoni P, Mussa A: [The technique of sentinel lymph nodes in patients with anus neoplasm]. Suppl Tumori; 2005 May-Jun;4(3):S32-3
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The technique of sentinel lymph nodes in patients with anus neoplasm].
  • [Transliterated title] La tecnica del linfonodo sentinella nei pazienti affetti da neoplasia dell'ano.
  • Anal cancer is a rare neoplasm, representing 1-2% of all large bowel cancers.
  • In order to assess inguinal lymph node status we applied the sentinel node technique to patients affected by anal cancer.
  • Considering the strong correlation between prognosis and node involvement, we consider this technique an important and simple method for evaluating the lymph node status and for an adequate pre-treatment staging of anal carcinoma. fundamental in the choice of radiation plane.
  • [MeSH-major] Anus Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437886.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Hosono S, Ohira M, Maeda K, Muguruma K, Nishihara T, Inoue T, Yashiro M, Hirakawa K: Synchronous adenocarcinomas of the ileum and transverse colon detected by capsule endoscopy: report of a case. Surg Today; 2006;36(7):663-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither gastrointestinal endoscopy nor computed tomography showed by abnormal findings; however, a capsule endoscopy, performed to detect obscure gastrointestinal bleeding, revealed a tumor in the ileum.
  • When we tried to take biopsies of the ileal tumor by push enteroscopy via the anus, we found another tumor in the transverse colon.
  • On exploration, tumors were identified in the ileum and the transverse colon.
  • [MeSH-major] Adenocarcinoma / pathology. Capsule Endoscopy. Colonic Neoplasms / pathology. Ileal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794807.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Aigner F, Boeckle E, Albright J, Kilo J, Boesmueller C, Conrad F, Wiesmayr S, Antretter H, Margreiter R, Mark W, Bonatti H: Malignancies of the colorectum and anus in solid organ recipients. Transpl Int; 2007 Jun;20(6):497-504
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the colorectum and anus in solid organ recipients.
  • A total of 3595 SOTs were performed between 1986 and 2005 at our center and retrospectively analyzed with regard to the incidence and course of malignancies of the colon, rectum, and anus.
  • Colorectal adenocarcinoma was diagnosed in nine patients (0.25%; mean age at diagnosis 65 years) at a mean of 5.3 years after transplantation.
  • Five patients (55%) died 7.2 years post-transplant due to cardiovascular disease (n = 4) and tumor progression (n = 1).
  • Four patients developed anal neoplasia (0.11%) 7 years post-transplant with 100% 1-year survival.
  • The incidence of anal but not of colorectal cancers in our transplant recipients differed from that of immunocompetent individuals of corresponding age (0.11% vs. 0.002% and 0.25% vs. 0.3%).
  • [MeSH-major] Anus Neoplasms / epidemiology. Colorectal Neoplasms / epidemiology. Immunosuppressive Agents / adverse effects. Organ Transplantation. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343685.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


9. Baatrup G, Bolstad M, Mortensen JH: Rigid sigmoidoscopy and MRI are not interchangeable in determining the position of rectal cancers. Eur J Surg Oncol; 2009 Nov;35(11):1169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE:. 1) To analyse for interchangeability of rigid sigmoidoscopy and MRI in determining the distance from anus to tumour, and to determine if anterior/posterior location influences this difference.
  • 2) To analyse the effect of preoperative chemo-radiotherapy on the distance from anus to tumour.
  • RESULTS: The mean distance from the anal verge to the tumour measured by sigmoidoscopy was 82mm and by MRI 61mm (p<0.01).
  • The length of the tumours decreased by 16mm after neoadjuvant treatment, but the distance from tumour to anus increased by only 4mm. CONCLUSION:.
  • 1) MRI and sigmoidoscopy are not interchangeable in determining the distance from anus to tumour simply by correcting for the length of the anal canal.
  • 2) The gain in tumour free distance above the anus induced by neoadjuvant treatment is small.
  • [MeSH-major] Anal Canal / pathology. Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249188.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Palefsky J: Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep; 2008 May;5(2):78-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and anal neoplasia.
  • Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection.
  • Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women.
  • Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).
  • HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer.
  • Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Papillomavirus Infections
  • [MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomaviridae / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510893.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


11. Divis P, Vlcek P, Capov I, Divisová K, Katolická J, Vanícek J, Kotulánová E: [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment]. Klin Onkol; 2010;23(6):421-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment].
  • The aim of the study was to compare the tumour volume reduction before and after the oncological therapy in relation to the change in the CEA value and to the outcome of the histopathological evaluation of response to the treatment.
  • The tumour volume before and after the CRT, percentage reduction in the tumour volume and the relation to the change in the CAE value and the histopathological evaluation were evaluated.
  • RESULTS: The distance between the anus and the tumour was from 3 to 15 centimetres, the average value being 8.1 centimetres.
  • In 5 cases the tumour was not histologically found in the resected specimen.
  • The average tumour volume before CRT was 32.48, range 10.3-88.5, after the CRT the average volume was 20.13, range 4.7-55.1.
  • This relation however has not been proved in the N value change.
  • Only in one-third of the evaluated patients was there a positive change in both T and N classification.
  • No relation between the CEA value and the tumour volume change has been proven.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Neoadjuvant Therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351419.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


12. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


13. Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV: Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum; 2005 Dec;48(12):2289-93
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases.
  • The analysis of our patients suggests that herpes simplex virus, Types 1 and 2, may cause verrucous lesions simulating neoplasia in patients with AIDS using antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / diagnosis. Herpes Simplex / diagnosis
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Humans. Hypertrophy. Immunohistochemistry. Inflammation. Male. Middle Aged. Recurrence


14. Mistrangelo M, Mobiglia A, Cassoni P, Castellano I, Maass J, Martina MC, Bellò M, Mussa A: [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases]. Suppl Tumori; 2005 May-Jun;4(3):S29-30
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases].
  • [Transliterated title] Il carcinoma verrucoso dell'ano o tumore di buschke-lowenstein dell'ano: stadiazione e trattamento presentazione di 3 casi.
  • INTRODUCTION: Giant condyloma acuminatum or Buschke Lowenstein tumor of the anorectal and perianal regions is an uncommon entity that commonly affects genitalia.
  • The hallmark of the disease is the high rate of recurrence (66%) and malignant transformation (56%).
  • MATERIALS AND METHODS: At the Oncological Surgical Department, University of Turin, three patients were diagnosed with a Buschke Lowenstein tumor.
  • In one case we observed a late anal stenosis treated with local dilatations.
  • One patient with a small persistence of the disease was treated with cryotherapy.
  • All inguinal nodes revealed negative to definitive histological exam, that confirmed the diagnosis of Buschke Lowenstein tumor of the primary lesion.
  • CONCLUSIONS: Buschke Lowenstein tumors are rare but extensive lesions difficult to treat.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / surgery. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Buschke Lowenstein Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437884.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV: Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum; 2009 Feb;52(2):239-47
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia.
  • PURPOSE: High-resolution anoscopy is colposcopy of the anus after applying 3 percent acetic acid.
  • High-resolution anoscopy with biopsy was used as the standard for detecting high-grade anal neoplasia and was compared to detection of high-grade anal neoplasia by anal cytology, human papillomavirus testing, or the combination.
  • A specimen was taken for anal cytology and human papillomavirus testing, followed by high-resolution anoscopy with biopsy of any lesions.
  • RESULTS: Ninety-one percent of HIV-positive and 57 percent of HIV-negative MSM had anal human papillomavirus infection.
  • In HIV-positive men the sensitivity of abnormal cytology to detect high-grade anal neoplasia was 87 percent, and in HIV-negative MSM it was 55 percent.
  • Among HIV-negative men, 9 of 20 cases of high-grade anal neoplasia would have been missed because cytology was negative, but the addition of human papillomavirus positivity increased sensitivity for the combination to 90 percent.
  • CONCLUSIONS: Sensitivity and specificity of anal cytology and human papillomavirus testing are different in HIV-positive and HIV-negative MSM for detecting high-grade anal neoplasia when patients have high-resolution anoscopy-guided biopsy of lesions.
  • High-resolution anoscopy is an effective tool for diagnosing high-grade anal neoplasia.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Endoscopy, Gastrointestinal. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Anus Diseases / diagnosis. Anus Diseases / virology. Biopsy. Cytodiagnosis. HIV Seronegativity. HIV Seropositivity / complications. Homosexuality. Humans. Male. Middle Aged. Polymerase Chain Reaction. Precancerous Conditions / diagnosis. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279418.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NIAID NIH HHS / AI / K23 AI054157; United States / NIAID NIH HHS / AI / R01 CA/AI 88739; United States / NCI NIH HHS / CA / R01 CA54053; United States / NCRR NIH HHS / RR / UL1 RR024131-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Zhang Y, Jorda M, Goldblum JR: Perianal mammary-type myofibroblastoma. Ann Diagn Pathol; 2010 Oct;14(5):358-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopically, the neoplasm was composed of bland spindled cells generally arranged into short fascicles with abundant myxoid stroma.
  • [MeSH-major] Anus Neoplasms / pathology. Breast Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20850700.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Desmin
  •  go-up   go-down


17. Kim HJ, Lee KY, Kim YW: Case report: Imaging features of perianal leiomyoma. Br J Radiol; 2009 Aug;82(980):e168-70
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A leiomyoma is a benign mesenchymal neoplasm that usually develops where smooth muscle is present.
  • The external anal sphincter was stretched over the surface of the leiomyoma and the internal anal sphincter was intact on surgery.
  • [MeSH-major] Anal Canal. Anus Neoplasms / diagnosis. Leiomyoma / diagnosis
  • [MeSH-minor] Adult. Contrast Media. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Radiol. 2010 Jan;83(985):88. Lee, G H [corrected to Lee, K Y]
  • (PMID = 19592401.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


18. Bège T, Turrini O, Lelong B, Delpero JR: Pelvic cancer recurrence: drop the arrow in the target. Surg Laparosc Endosc Percutan Tech; 2009 Apr;19(2):e41-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 53-year-old woman presented in 2006 with a small (20 mm) pelvic recurrence of an anal canal cancer initially treated by radiochemotherapy and amputation of the rectum.
  • [MeSH-major] Anus Neoplasms / pathology. Neoplasm Recurrence, Local. Pelvic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390261.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yang R, Cheung MC, Zhuge Y, Armstrong C, Koniaris LG, Sola JE: Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases. J Surg Res; 2010 Jun 15;161(2):209-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases.
  • OBJECTIVE: To study the outcomes of solid tumors of the colon and rectum in pediatric patients.
  • RESULTS: Overall, 270 patients with malignant tumors of the lower gastrointestinal tract were identified.
  • The annual incidence was 1.04 cases per million in 2005.
  • The majority of tumors arose in adolescents (68.1% were older than 15 y).
  • Tumors were more commonly seen in white (77.8%) and non-Hispanic (78.9%) patients.
  • Tumors were identified in the right colon (45.9%), transverse colon (9.3%), left colon (20.4%), rectum (15.2%), and anal canal (1.1%).
  • The most common histology of these tumors was adenocarcinoma (35.6%), followed by carcinoid (34.1%).
  • Disease specific 5- and 10-y-survival for the entire cohort was 61.0% and 57.9%, respectively.
  • Multivariate analysis of the cohort identified tumor stage (HR 8.39, P < 0.001 for distant disease), tumor type (signet ring HR 2.12, P = 0.025, and carcinoid HR = 0.14, P = 0.001), and surgical resection (no surgery HR 2.98, P = 0.010) as independent predictors of worse outcome.
  • CONCLUSION: In the pediatric population, solid tumors of the colon and rectum occur more frequently in the right side of the colon in teenagers.
  • Surgical resection significantly improves survival for most pediatric tumors of the lower gastrointestinal tract.
  • [MeSH-major] Colonic Neoplasms / epidemiology. Colonic Neoplasms / surgery. Colorectal Neoplasms / epidemiology. Rectal Neoplasms / epidemiology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Aging. Anus Neoplasms / epidemiology. Anus Neoplasms / mortality. Anus Neoplasms / pathology. Child. Child, Preschool. Colectomy. Continental Population Groups / statistics & numerical data. Ethnic Groups / statistics & numerical data. Female. Humans. Incidence. Male. Neoplasm Staging. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19285688.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • Patient-, tumour-, and treatment-factors were tested for influence on survival and local control using Cox multivariate analysis.
  • With median follow-up of 8.0 years for surviving patients (3.9 years including deceased patients), five-year overall survival and disease-free-survival were 57% and 51%, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Meyer JJ, Willett CG, Czito BG: Emerging role of intensity-modulated radiation therapy in anorectal cancer. Expert Rev Anticancer Ther; 2008 Apr;8(4):585-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although radiation therapy has an established role to play in the management of rectal and anal tumors, there are often treatment-related morbidities that negatively impact on patients.
  • It has been implemented in the treatment of prostate and head and neck tumors with success.
  • This article reviews the rationale for its use in treating anorectal tumors and discusses early clinical data supporting its continued investigation.
  • [MeSH-major] Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402525.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 58
  •  go-up   go-down


22. Gretschel S, Warnick P, Bembenek A, Dresel S, Koswig S, String A, Hünerbein M, Schlag PM: Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol; 2008 Aug;34(8):890-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal.
  • AIM: Although 15-25% of patients with anal cancer present with superficial inguinal lymph node metastases but the routine application of groin irradiation is controversial because of serious side effects.
  • METHODS: Forty patients with anal cancer underwent 1 ml Tc(99m)-Nanocolloid injection in four sites around the tumour.
  • In 10/20 patients SLNB altered the therapy plan--four patients with T1-tumours and positive SLN had additional groin irradiation, whereas 6 patients with small T2-tumors and tumour-free inguinal SLN did not undergo inguinal irradiation.
  • CONCLUSIONS: Inguinal sentinel node biopsy in anal cancer is efficient and could assist in the decision for inguinal radiation.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178364.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin
  •  go-up   go-down


23. Sanli Y, Turkmen C, Kurul S, Taş F, Mudun A, Cantez S: Sentinel lymph node biopsy for the staging of anal melanoma: report of two cases. Ann Nucl Med; 2006 Nov;20(9):629-31
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy for the staging of anal melanoma: report of two cases.
  • Primary melanoma of the anal region is a rare pathological entity and its prognosis is generally poor.
  • The aim of this report is to demonstrate the feasibility of the sentinel lymph node (SLN) procedure with combined technique in patients with anal melanoma.
  • We report of two cases with anal melanoma that had wide local excision of the primary lesion and was referred for further evaluation.
  • After diagnostic metastatic work-up, SLN procedure consisted of a combination of preoperative lymphoscintigraphy with technetium-99m nanocolloid injected around the tumor, and intraoperative detection of SLN with gamma probe (combined technique) was performed.
  • In addition, patent blue dye was injected at the periphery of the tumor to facilitate direct identification of the blue-stained lymph node.
  • Consequently, we suggest that SLN procedure with combined technique is also a useful technique in malignant melanomas similar to other anal canal cancers.
  • [MeSH-major] Anus Neoplasms / diagnosis. Lymph Nodes / pathology. Melanoma / diagnosis. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Radionuclide Imaging / methods. Technetium Tc 99m Sulfur Colloid / pharmacology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294674.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


24. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • RESULTS: At the end of RT with concomitant chemotherapy local tumor clinical complete response rate was 83%.
  • Out of 5 local tumor relapses, 3 were salvaged with APR.
  • The overall local tumor control (LC) rate with or without salvage local treatment were 88%.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • The 5-year disease-free survival was 75%.
  • After multivariate analysis, 2 independent predicting factors significantly influenced the disease-free survival: HIV-positive pts (negative vs positive, P=0.032) and clinical tumor response after the first course of radiotherapy (<50% vs >or=50%, P=0.00032).
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • The clinical tumor response after the first course of RT and concomitant chemotherapy is probably the most important predictive factor on the disease-free survival.
  • For patients with T3 or T4 lesion and tumor regression <or=50% after the first course of radiation therapy, surgical non conservative treatment should be discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Zhong J, Zhou JN, Xu FP, Shang JQ: [Diagnosis and treatment of anorectal malignant melanoma--a report of 22 cases with literature review]. Ai Zheng; 2006 May;25(5):619-24
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of anorectal malignant melanoma--a report of 22 cases with literature review].
  • BACKGROUND & OBJECTIVE: Anorectal malignant melanoma (AMM) is an aggressive malignant tumor, and its treatment still remains controversial.
  • This study was to summarize our experience on diagnosis and treatment of AMM.
  • METHODS: Clinicopathologic records, including clinical feature, diagnosis, operation patterns, and prognosis, of 22 patients with AMM, treated in Jiangsu Provincial Cancer Hospital from 1977 to 2003, were analyzed retrospectively with literature review.
  • RESULTS: The 22 patients with AMM accounted for 0.04% of all the patients diagnosed as malignant tumors of large bowel simultaneously in our hospital.
  • The most common complaints of AMM patients were hematochezia (86%), anus pain or discomfort (59%), local mass (27%), and so on.
  • The definite pathologic diagnosis rate before surgery was 48%.
  • CONCLUSIONS: AMM is a rare disease with poor prognosis.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / surgery. Melanoma / diagnosis. Melanoma / surgery. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Antigens, Neoplasm / metabolism. Chemotherapy, Adjuvant. Colostomy. Diagnostic Errors. Female. Follow-Up Studies. Hemorrhoids / diagnosis. Humans. Liver Neoplasms / secondary. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Rectum / surgery. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687086.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 13
  •  go-up   go-down


26. Gurfinkel R, Walfisch S: Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis. Tech Coloproctol; 2005 Dec;9(3):235-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis.
  • The optimal treatment of metastatic anal carcinomas is controversial.
  • We present the case of 54-year-old woman with a diagnosis of metastatic basaloid anal carcinoma.
  • The patient underwent resection of liver metastasis in combination with cisplatin + 5FU and local radiotherapy, without evident disease 3 years after diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328122.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Pineda CE, Berry JM, Welton ML: High resolution anoscopy and targeted treatment of high-grade squamous intraepithelial lesions. Dis Colon Rectum; 2006 Jan;49(1):126
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of this video is to illustrate the use of high resolution anoscopy in the diagnosis and treatment of anal high-grade squamous intraepithelial lesions.
  • METHODS: Five patients with anal dysplasia were examined in the operating room with acetic acid and the operative microscope.
  • Acetowhite lesions with specific vascular characteristics like punctuate vessels or honeycomb patterns are highly suggestive of high-grade disease.
  • Some pigmented lesions contain high-grade squamous intraepithelial lesions; the operative microscope is used in this setting to look for the vascular characteristics of high-grade disease.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Colonoscopy / methods. Image Enhancement. Video-Assisted Surgery / methods
  • [MeSH-minor] Humans. Male. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222485.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections
  • [MeSH-minor] Diagnosis, Differential. HIV Infections / complications. Humans. Papillomaviridae / pathogenicity

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


29. Yamamoto S, Fukunaga M, Miyajima N, Okuda J, Konishi F, Watanabe M, Japan Society of Laparoscopic Colorectal Surgery: Impact of conversion on surgical outcomes after laparoscopic operation for rectal carcinoma: a retrospective study of 1,073 patients. J Am Coll Surg; 2009 Mar;208(3):383-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A total of 1,073 patients with carcinoma of the rectum and anus who underwent laparoscopic operations were reviewed retrospectively.
  • [MeSH-major] Digestive System Surgical Procedures. Laparoscopy. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Body Mass Index. Female. Humans. Intraoperative Complications / classification. Intraoperative Complications / epidemiology. Intraoperative Complications / etiology. Length of Stay. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Postoperative Complications / classification. Postoperative Complications / epidemiology. Postoperative Complications / etiology. Postoperative Hemorrhage / epidemiology. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318000.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Watanabe M; Kokuba Y; Konishi F; Kawamura Y; Miyajima N; Fukunaga M; Kudo S; Tanaka J; Tanigawa N; Okuda J; Nagai H; Otsuka K; Fukunaga Y; Okajima M; Bandou H; Kitano S; Inomata M; Kubo Y; Ichihara T; Hasegawa H; Yamamoto S; Ikoma S; Nishiyama Y; Sugihara K; Yamaguchi S; Sekimoto M; Masaki M; Idani H; Sumiyama Y; Saida Y; Munemoto Y; Maeda K; Hanai K; Kuroyanagi H; Ueda K
  •  go-up   go-down


30. Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Nørgaard M, Laurberg S: Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol; 2009 Jan;16(1):68-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap.
  • Salvage surgery of recurrent or persistent anal cancer following radiotherapy is often followed by perineal wound complications.
  • We examined survival and perineal wound complications in anal cancer salvage surgery during a 10-year period with primary perineal reconstruction predominantly performed using vertical rectus abdominis myocutaneous (VRAM) flap.
  • Between 1997 and 2006, 49 patients underwent anal cancer salvage surgery.
  • We conclude that anal cancer salvage surgery can yield long-time survival but obtaining free margins is critical.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Perineum / surgery. Reconstructive Surgical Procedures. Rectus Abdominis / transplantation. Surgical Flaps. Wound Healing
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / therapy. Salvage Therapy. Survival Rate. Time Factors. Treatment Outcome


31. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • There were no differences between patients with relapse (n=22) or persistence (n=15) of disease.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy / methods. Disease-Free Survival. Endosonography. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. New York / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Honjo Y, Bian Y, Kawakami K, Molinolo A, Longenecker G, Boppana R, Larsson J, Karlsson S, Gutkind JS, Puri RK, Kulkarni AB: TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. Cell Cycle; 2007 Jun 1;6(11):1360-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transplantation of these tumors into athymic nude mice resulted in 62% tumorigenicity.
  • To determine whether evasion of the immune response plays any role in this tumorigenesis, we analyzed the expression levels of receptors for interleukin-13 (mIL-13R), a key negative regulator of tumor immunosurveillance, and found that 33% of COKO tumors expressed the IL-13R alpha2 chain.
  • This is the first demonstration that loss of TbetaRI can lead to spontaneous tumor formation.
  • [MeSH-major] Activin Receptors, Type I / physiology. Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Head and Neck Neoplasms / genetics. Neoplastic Syndromes, Hereditary / genetics. Receptors, Transforming Growth Factor beta / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Brain / embryology. Brain / metabolism. Cell Line, Tumor / drug effects. Crosses, Genetic. Drug Screening Assays, Antitumor. Exotoxins / pharmacology. Female. Genes, Synthetic. Integrases / genetics. Interleukin-13 / pharmacology. Interleukin-13 Receptor alpha2 Subunit / biosynthesis. Interleukin-13 Receptor alpha2 Subunit / genetics. Male. Mice. Mice, Knockout. Mice, Nude. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Transplantation. Neurofilament Proteins / genetics. Organ Specificity. Protein-Serine-Threonine Kinases. Recombinant Fusion Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534148.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Exotoxins; 0 / IL13-PE38; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Recombinant Fusion Proteins; 108688-71-7 / neurofilament protein H; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


33. Allal AS, Bründler MA, Gervaz P: Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis; 2005 Mar;20(2):161-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
  • BACKGROUND: Histologically, tumors of the anal region are either keratinizing (K) or non-keratinizing (NK) squamous cell carcinomas (SCCA).
  • METHODS: We performed an immunohistochemical analysis on 98 pre-treatment biopsies of patients with anal canal cancers.
  • Expression of p53 and Bcl-2 was considered positive when >5% of tumor cells were stained.
  • Tumor histology was correlated with protein expression as well as with other clinical variables.
  • The proportion of Bcl-2 positive tumors was statistically higher in NK carcinomas (51.5 vs. 23.5%, p=0.009).
  • In addition, women were more likely than men to present with NK carcinomas (71 vs. 45%, p=0.03) as well as with Bcl-2 positive tumors (47 vs. 29%, p=0.05).
  • The more distal the tumor is (anal margin), the more frequently the keratinizing subtype is observed (87 vs. 23%, p=0.0002).
  • By contrast, there was no correlation between p53 and tumor histology (p=0.83).
  • In addition, significant differences were observed in the distribution of these two histological subtypes according to gender and tumor sublocation.
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma, Squamous Cell / metabolism. Keratinocytes / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biopsy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Sex Factors. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688099.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


34. Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X: Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Dis Colon Rectum; 2009 Jun;52(6):1130-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era.
  • PURPOSE: This study aimed to determine the prevalence of macroscopic anal lesions and associated factors in HIV-infected outpatients during the era of highly active antiretroviral therapy.
  • METHODS: A randomly selected sample of patients with HIV-infection receiving follow-up care in the infectious diseases department of Bichat University Hospital was invited to participate in a systematic screening program consisting of anal examination with anoscopy and a standardized questionnaire.
  • Overall, 208 patients (44 percent) had at least one anal macroscopic lesion: 108 patients (22.8 percent) had human papilloma (HPV)-related lesions (condyloma with or without dysplasia), 67 (14.2 percent) had hemorrhoidal disease, 50 (10.6 percent) had anal fissures, and 44 (9.3) percent had other anal lesions.
  • Independent significantly associated factors for anal condyloma were history of anal condyloma (OR, 2.09) and median number of episodes of sexual intercourse per month (OR, 1.03) in men who have sex with men; history of genital condyloma (OR, 26.74), and unprotected sexual intercourse (OR, 7.47) in heterosexual men; and CD4 cell count below 200/mm3 (OR, 6.02), receptive anal intercourse (OR, 6.37), and history of anal condyloma (OR, 16.69) in women.
  • Neither sexual behavior nor characteristics related to HIV infection were associated with hemorrhoidal disease or anal fissure.
  • CONCLUSIONS: Because patients with HIV infections have a high prevalence of unreported anal lesions that may be highly contagious, involve risk of anal neoplasia, or negatively affect quality of life, systematic anal screening should be conducted in the HIV-infected population.
  • [MeSH-major] Anus Diseases / epidemiology. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2010 Mar;53(3):364-5 [20173491.001]
  • (PMID = 19581857.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Goto H, Ikenaga M, Yasui M, Miyazaki M, Mishima H, Tsujie M, Miyamoto A, Hirao M, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2659-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation].
  • A 76-year-old woman consulted her local physician because she experienced anal pain during defecation.
  • She was diagnosed with squamous cell anal carcinoma and underwent chemoradiation (59.4 Gy + UFT 500 mg/5 days/week).
  • The examinations after chemoradiation revealed a complete remission of the tumor.
  • She was followed up and 8 months later, she experienced anal erosion and pain.
  • Abdominoperineal resection (APR) was performed as salvage treatment, and she has been disease free for 10 months.
  • Functional preservation employing concomitant chemoradiation has become the standard treatment for most case of squamous cell anal carcinoma, with APR backup being a salvage procedure.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Salvage Therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Neoplasm Recurrence, Local. Tegafur / therapeutic use. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224671.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


36. Vilbergsson E, Isaksson HJ, Möller PH: [Case report: facial skin metastasis from rectal adenocarcinoma]. Laeknabladid; 2010 Feb;96(2):109-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colonoscopy revealed a tumor located 10 to 15cm from the anus.
  • The tumor was not resected due peritoneal dissemination and a tumor invasion into the urinary bladder, found intraoperatively.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Facial Neoplasms / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy. Colonoscopy. Humans. Male. Neoplasm Invasiveness. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118505.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


37. Cumberland L, Dana A, Resh B, Fitzpatrick J, Goldenberg G: Verruciform xanthoma in the setting of cutaneous trauma and chronic inflammation: report of a patient and a brief review of the literature. J Cutan Pathol; 2010 Aug;37(8):895-900
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VX is a rare benign mucocutaneous neoplasm that typically presents as a solitary lesion with a predilection for the oral cavity, although extra-oral lesions have been reported involving the vulva, scrotum, penis, anal region and extremities.
  • A significant number of VXs of the skin have been found to co-exist with cutaneous disorders including graft vs. host disease, discoid lupus erythematosus, pemphigus vulgaris, and recessive dystrophic epidermolysis bullosa.
  • [MeSH-major] Anus Diseases / pathology. Xanthomatosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2012 Mar;39(3):391-4 [21362016.001]
  • (PMID = 19958440.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


38. Lee MW, Chung WK, Choi JH, Moon KC, Koh JK: A case of botryoid-type embryonal rhabdomyosarcoma. Clin Exp Dermatol; 2009 Dec;34(8):e737-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe an infant with a congenital polypoid anal mass, diagnosed as botryoid-type embryonal rhabdomyosarcoma.
  • Tumour cells were strongly immunoreactive for desmin and 10% of cells displayed immunoreactivity for myoglobin.
  • We present this case with a view to highlighting the benign clinical and histological appearance of botryoid-type embryonal rhabdomyosarcoma.
  • [MeSH-major] Anus Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology
  • [MeSH-minor] Desmin / analysis. Early Detection of Cancer. Humans. Infant. Male. Neoplasm Proteins / analysis. Prognosis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663848.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Desmin; 0 / Neoplasm Proteins
  •  go-up   go-down


39. Branco BC, Sachar DB, Heimann T, Sarpel U, Harpaz N, Greenstein AJ: Adenocarcinoma complicating restorative proctocolectomy for ulcerative colitis with mucosectomy performed by Cavitron Ultrasonic Surgical Aspirator. Colorectal Dis; 2009 May;11(4):428-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CUSA was introduced to simplify and optimize ileal pouch-anal anastomosis with mucosectomy and has been shown to shorten the operative time and reduce blood loss.
  • In the present case, even though preoperative colonoscopy had clearly shown dysplasia, the surgical pathology report could not detect any neoplasia in the specimen; hence, the patient was not surveyed for pouch cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Anus Neoplasms / surgery. Colitis, Ulcerative / surgery. Neoplasm Recurrence, Local. Proctocolectomy, Restorative / methods. Vaginal Neoplasms / secondary


40. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • The 5-year disease-specific survival (DSS) and overall survival (OS) rates were respectively 86% (95% CI, 72-99%) and 55% (95% CI, 44-66%).
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • CONCLUSIONS: We conclude that definitive RT and/or BT yield a good local control and disease-specific survival comparable with published data.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Laytragoon-Lewin N, Nilsson PJ, Castro J, Gharizadeh B, Nyren P, Glimelius B, Elmberger G, Turesson I, Svensson C: Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous cell carcinoma patients. Anticancer Res; 2007 Nov-Dec;27(6C):4473-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous cell carcinoma patients.
  • In this study, the role of HPV in 72 patients with anal squamous cell carcinoma was investigated.
  • RESULTS: Ninety percent of the carcinoma biopsies carried high-risk oncogenic HPV in their malignant cells.
  • The HPV genome in the tumour cell influenced significantly the host cell cycle progression, but not DNA aberrations.
  • Within these patients, HPVstatus in the malignant cells was not found to be associated with patient survival time.
  • CONCLUSION: High-risk oncogenic HPV may play an important role in the initiation of host cell proliferation in anal squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / genetics. Anus Neoplasms / virology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / virology. DNA, Neoplasm / genetics. Papillomaviridae. Tumor Virus Infections

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214063.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


42. Sturgeon BP, Milne EM, Smith KC: Benign peripheral nerve sheath tumor of the perianal region in a young pony. J Vet Diagn Invest; 2008 Jan;20(1):93-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign peripheral nerve sheath tumor of the perianal region in a young pony.
  • On the basis of the histopathology and immunohistochemistry, a diagnosis of benign peripheral nerve sheath tumor (schwannoma type) was made.
  • This case was unusual in that the concentric laminations of Schwann cells were very loosely arranged, with an intervening myxomatous stroma (Antoni type B appearance) and despite its benign histological appearance, the mass extended deeply to the proximal sacral vertebrae.
  • [MeSH-major] Anus Neoplasms / veterinary. Horse Diseases / pathology. Nerve Sheath Neoplasms / veterinary
  • [MeSH-minor] Animals. Horses. Immunohistochemistry / veterinary. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182519.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Wakefield LM, Stuelten C: Keeping order in the neighborhood: new roles for TGFbeta in maintaining epithelial homeostasis. Cancer Cell; 2007 Oct;12(4):293-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TGFbetas are thought to have tumor suppressor activity in many organ systems, but receptor inactivation in mouse models has not previously resulted in increased spontaneous tumorigenesis.
  • [MeSH-minor] Animals. Anus Neoplasms / metabolism. Anus Neoplasms / pathology. Cell Movement. Extracellular Matrix / metabolism. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Homeostasis. Humans. Integrins / metabolism. Keratin-14 / genetics. Keratinocytes / metabolism. Keratinocytes / pathology. Mice. Mice, Knockout. Mutation. Neoplasm Invasiveness. Papilloma / metabolism. Papilloma / pathology. Promoter Regions, Genetic. Skin / metabolism. Skin / pathology. Skin / physiopathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Time Factors. Urogenital Neoplasms / metabolism. Urogenital Neoplasms / pathology. Wound Healing. ras Proteins / genetics. ras Proteins / metabolism. src-Family Kinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • (PMID = 17936552.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrins; 0 / KRT14 protein, human; 0 / Keratin-14; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


44. Nadal SR, Horta SH, Calore EE, Manzione CR: [Outcome of treatment of anal squamous cell carcinoma and its precursor in HIV-infected patients]. Rev Assoc Med Bras (1992); 2007 Jul-Aug;53(4):365-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of treatment of anal squamous cell carcinoma and its precursor in HIV-infected patients].
  • [Transliterated title] Resultados do tratamento do carcinoma espinocelular anal e do seu precursor em doentes HIV-positivos.
  • OBJECTIVE: Incidence of anal squamous cell carcinoma is increasing mainly among HIV-positive patients.
  • Treatment consists of radiotherapy and chemotherapy, sometimes followed by tumor resection.
  • This is a report of cases treated at the "Instituto de Infectologia Emílio Ribas", Sao Paulo, Brazil.
  • Thirty patients had high grade anal intra-epithelial neoplasia (HAIN), treated with local resection, and 15 with anal canal invasive squamous cell carcinoma were first submitted to chemo radiation, while biopsies were obtained during follow-up.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Seropositivity. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Treatment Failure. Treatment Outcome. Treatment Refusal / statistics & numerical data

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823743.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


45. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ: Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol; 2007 Oct;14(10):2780-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
  • BACKGROUND: For patients with anal canal cancer who fail combined modality treatment (CMT), salvage surgery (SS) offers the potential for long term survival.
  • METHODS: We identified 60 patients with persistent or recurrent anal cancer who had undergone SS; 20 were excluded.
  • Overall and disease-free survival (OS, DFS) curves were constructed using the Kaplan Meier method.
  • Median OS was 41 months; OS and disease free survival at 5 years were 39% and 30%, respectively.
  • Independent predictors of poor OS were male gender, Charlson Comorbidity Score and tumor size.
  • Independent predictors of poor disease free survival were positive margins and lymphovascular invasion.
  • CONCLUSION: SS for anal canal cancer was associated with significant morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Cancer Care Facilities. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ontario. Registries. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638059.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Kiss H: [Challenging conversation with a patient about the change in treatment strategy from a curative to a palliative setting]. Wien Med Wochenschr; 2006 May;156(9-10):324-6
MedlinePlus Health Information. consumer health - Talking With Your Doctor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Aufklärungsgespräch mit einer Patientin über den Wechsel des Behandlungsansatzes vom kurativen zum palliativen Setting.
  • Patient information regarding therapeutic strategies, especially when treatments are suggested to alleviate symptoms and are not curing the disease can be the most challenging part.
  • However, she did not consent to the necessary treatment, completely refusing to recognize the seriousness of her disease.
  • In spite of many attempts to enlighten her, the disease was allowed to progress, and it was only when thrombosis caused massive edema of the right leg that the patient finally started to ask about prognosis and potential treatment.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Palliative Care / psychology. Patient Education as Topic. Physician-Patient Relations. Rectal Neoplasms / therapy. Truth Disclosure
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Female. Home Nursing / psychology. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / psychology. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / psychology. Neoplasms, Multiple Primary / therapy


47. Tomimaru Y, Ohue M, Noura S, Tanida T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1776-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer].
  • A 63-year-old man with a history of anal fistula was admitted to our hospital because the anal pain didn't disappear after the operation.
  • On digital examination, a hard mass measuring 3.0 cm in diameter was found at the anal canal.
  • Colonoscopy revealed another rectal cancer at 15 cm from anal verge.
  • Biopsy of the tumor also showed moderately differentiated adenocarcinoma, resembling the anal canal tumor.
  • Because the histological findings of both tumors were nearly identical, we considered that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal fistula.
  • The patient underwent anterior resection for the rectal cancer, and a local resection for the anal canal cancer.
  • Immunohistochemical staining for Ki-67, p53, Muc2, CD10, CK-7, and CK-20 revealed similar patterns in both tumors.
  • Additionally, genetic analysis for p53, K-ras, and MSI revealed similar patterns in both tumors.
  • We may suggest from these results that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / complications. Rectal Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Seeding


48. Chapet O, Gerard JP, Riche B, Alessio A, Mornex F, Romestaing P: Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1316-24
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer.
  • PURPOSE: To evaluate whether the tumor response after an initial course of irradiation predicts for colostomy-free survival and overall survival in patients with anal canal cancer.
  • An evaluation of tumor regression, before the boost, was available for 221 patients.
  • They were divided into four groups according to the tumor response: <70%, 70-80%, >80% but <100%, and 100%.
  • The disease-free survival rate was 60.0% +/- 3.3% and 49.4% +/- 3.9% at 5 and 10 years, respectively.
  • Two groups could be differentiated according to the percentage of tumor regression before the boost: >80% vs. < or = 80%.
  • The group with a T3-T4 lesion and tumor regression < or = 80% had the poorest overall (52.8% +/- 12.3%), disease-free (19.9% +/- 9.9%), and colostomy-free survival (24.8% +/- 11.2%) rates.
  • CONCLUSION: The amount of tumor regression before EBRT or brachytherapy boost is a strong prognostic factor of disease control without colostomy.
  • When regression is < or = 80% in patients with an initial T3-T4 lesion, the use of conservative RT should be carefully evaluated because of the very poor disease-free and colostomy-free survival.
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Brachytherapy. Colostomy. Disease-Free Survival. Female. Humans. Iridium Radioisotopes / therapeutic use. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169674.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


49. Hida J, Okuno K, Yasutomi M, Yoshifuji T, Matsuzaki T, Uchida T, Ishimaru E, Tokoro T, Shiozaki H: Number versus distribution in classifying regional lymph node metastases from colon cancer. J Am Coll Surg; 2005 Aug;201(2):217-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the Japanese General Rules for Clinical and Pathologic Studies on Cancer of the Colon, Rectum, and Anus (JGR), node metastases are classified into four grades based on the distribution of metastatic nodes.
  • RESULTS: The case distribution by the JGR grading was 41.5% in n (-), 29.3% in n1 (+), 18.3% in n2 (+), and 11.0% in n3 (+) disease.
  • In the TNM classification, the distribution was 23.8% in pN1 and 34.8% in pN2 disease.
  • The 5-year survival rate by the JGR was 98.4% in n (-), 74.3% in n1 (+), 51.2% in n2 (+), and 30.0% in n3 (+) disease; in TNM classification, this rate was 76.0% in pN1 and 45.0% in pN2 disease.
  • [MeSH-major] Colonic Neoplasms / classification. Colonic Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Cecal Neoplasms / pathology. Colon / blood supply. Dissection. Guideline Adherence / standards. Humans. Japan / epidemiology. Lymph Node Excision. Multivariate Analysis. Practice Guidelines as Topic. Prognosis. Proportional Hazards Models. Risk Factors. Sigmoid Neoplasms / pathology. Survival Analysis. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038819.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


50. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • Of the 69 patients, 66 received radiotherapy (RT) and 3 with in situ disease were treated by local excision alone without RT.
  • Four patients developed local failure outside the initial tumor bed.
  • The 5-year overall survival, colostomy-free survival, and disease-free survival rate was 94%, 85%, and 89%, respectively.
  • CONCLUSION: Most recurrences occurred after a long disease-free interval after treatment and often outside the initial tumor site.
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Palefsky J: Human papillomavirus infection in HIV-infected persons. Top HIV Med; 2007 Aug-Sep;15(4):130-3
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rates of cervical and anal human papillomavirus (HPV) infection and abnormal cytology are high in HIV-infected women, as are rates of anal HPV infection and abnormal cytology in HIV-infected men who have sex with men (MSM).
  • Available evidence indicates that the incidence of anal cancer in HIV-infected MSM has increased in association with prolonged life expectancy achieved with antiretroviral therapy.
  • Routine screening for cervical neoplasia is recommended for HIV-infected women.
  • Routine screening is not yet universally recommended for anal neoplasia, although it should be considered for at-risk patients, particularly given recent improvements in local treatments.
  • Its potential benefit in preventing anal infection in women and men has yet to be determined, and its potential utility in those with HIV infection remains unknown.
  • [MeSH-major] Anus Neoplasms / epidemiology. HIV Infections / epidemiology. Papillomavirus Infections / epidemiology. Papillomavirus Vaccines. Uterine Cervical Neoplasms / epidemiology


52. Vajdic CM, Anderson JS, Hillman RJ, Medley G, Grulich AE: Blind sampling is superior to anoscope guided sampling for screening for anal intraepithelial neoplasia. Sex Transm Infect; 2005 Oct;81(5):415-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blind sampling is superior to anoscope guided sampling for screening for anal intraepithelial neoplasia.
  • OBJECTIVES: Anal cytology smears are either collected "blind" (swab inserted 4 cm into anal canal and rotated) or guided through an anoscope (transformation zone visualised and then sampled).
  • CONCLUSIONS: Blind cytology smears are superior to anoscope guided smears for screening for anal neoplasia in homosexual men.
  • [MeSH-major] Anus Neoplasms / pathology. Homosexuality, Male. Proctoscopy / methods. Specimen Handling / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1986 Sep 20;2(8508):657-60 [2876137.001]
  • [Cites] Sex Transm Infect. 1999 Jun;75(3):172-7 [10448395.001]
  • [Cites] Genitourin Med. 1988 Dec;64(6):378-82 [2852158.001]
  • [Cites] JAMA. 1990 Jun 6;263(21):2911-6 [2160023.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):203-6 [2166709.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):214-9 [2166710.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Genitourin Med. 1991 Apr;67(2):92-8 [1851723.001]
  • [Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]
  • [Cites] Sex Transm Dis. 1993 May-Jun;20(3):147-51 [8390103.001]
  • [Cites] Gastroenterology. 1993 Sep;105(3):658-66 [8359638.001]
  • [Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] Br J Surg. 1995 Apr;82(4):473-4 [7613888.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Obstet Gynecol. 2002 Jun;99(6):1053-9 [12052599.001]
  • [Cites] Obstet Gynecol. 2003 Aug;102(2):266-72 [12907098.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] Br J Vener Dis. 1984 Jun;60(3):205 [6329409.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]
  • [Cites] Cytopathology. 1998 Feb;9(1):15-22 [9523124.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] J Infect Dis. 1998 Jul;178(1):45-52 [9652422.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • (PMID = 16199742.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1745038
  •  go-up   go-down


53. Palefsky J: Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS; 2009 Jan;4(1):52-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related disease in people with HIV.
  • This review will describe recent findings in HPV-associated cancer incidence since the introduction of antiretroviral therapy, HPV/disease prevalence at sites other than cervix and anus, and recent data on screening and treatment of anal intraepithelial neoplasia.
  • RECENT FINDINGS: Consistent with high prevalence of anogenital HPV infection, new data on cervical intraepithelial neoplasia and anal intraepithelial neoplasia in HIV-positive men and women show that the incidence of cervical cancer has not declined since the introduction of antiretroviral therapy and that the incidence of anal cancer is rising.
  • Several studies also highlight high rates of HPV infection and HPV-associated disease at sites other than the cervix and anus, including the penis and the mouth.
  • Treatment methods for anal intraepithelial neoplasia have been described and show reasonable efficacy.
  • SUMMARY: New data imply that the problem of HPV-related cancers will not decline among HIV-positive men and women in the antiretroviral therapy era, highlighting the need to perform studies to determine if screening and treatment of anal intraepithelial neoplasia will prevent development of anal cancer.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2316-24 [18385760.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):103-7 [18472205.001]
  • [Cites] J Oral Pathol Med. 2008 Oct;37(9):555-9 [18355174.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Int J STD AIDS. 2007 Aug;18(8):538-42 [17686215.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • (PMID = 19339939.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-08; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA054053-08; United States / NCI NIH HHS / CA / R01 CA088739-03; United States / NCI NIH HHS / CA / CA088739-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS94538; NLM/ PMC2756707
  •  go-up   go-down


54. Menkarios C, Azria D, Laliberté B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Aillères N, Fenoglietto P: Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol; 2007;2:41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans.
  • BACKGROUND: To compare the dosimetric advantage of three different intensity-modulated radiation therapy (IMRT) plans to a three dimensional (3D) conventional radiation treatment for anal cancer with regards to organs-at-risk (OAR) avoidance, including iliac bone marrow.
  • METHODS: Five patients with T1-3 N0-1 anal cancer and five with T4 and/or N2-3 tumors were selected.
  • Clinical tumor volume (CTV) included tumor, anal canal and inguinal, peri-rectal, and internal/external iliac nodes (plus pre-sacral nodes for T4/N2-3 tumors).
  • CONCLUSION: IMRT is superior to 3D conformal radiation treatment for anal carcinoma with respect to OAR sparing, including bone marrow sparing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2006 Oct;176(4 Pt 1):1415-9 [16952647.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(1):82-6 [16983394.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):160-6 [17222931.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39 [7713791.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1731-6 [8625041.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16 [11240231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):275-80 [11730997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1388-96 [12459361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Phys Med Biol. 1961 Jan;5:255-8 [13726497.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):274-81 [16111597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • (PMID = 18005443.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2204019
  •  go-up   go-down


55. De Dosso S, Martin V, Zanellato E, Frattini M, Saletti P: Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori; 2010 Jul-Aug;96(4):627-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.
  • There are no standard chemotherapeutic options for patients with squamous cell anal carcinoma, relapsing and progressing on palliative cisplatin-based regimens.
  • Similarly to other malignant conditions, monoclonal antibodies directed against the epidermal growth factor receptor may represent an attractive therapeutic strategy.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Disease Progression. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20968146.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


56. de Jong JS, Beukema JC, van Dam GM, Slart R, Lemstra C, Wiggers T: Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol; 2010 Oct;17(10):2656-62
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up.
  • BACKGROUND: Selection of patients with anal cancer for groin irradiation is based on tumor size, palpation, ultrasound, and fine needle cytology.
  • Current staging of anal cancer may result in undertreatment in small tumors and overtreatment of large tumors.
  • This study reports the feasibility of the sentinel lymph node biopsy (SLNB) in patients with anal cancer and whether this improves the selection for inguinal radiotherapy.
  • METHODS: A total of 50 patients with squamous anal cancer were evaluated prospectively.
  • Patients without a SLNB (n = 29) received irradiation of the inguinal lymph nodes based on lymph node status, tumor size, and location of the primary tumor.
  • However, 2 patients with a tumor-free SLN and no inguinal irradiation developed lymph node metastases after 12 and 24 months, respectively.
  • CONCLUSIONS: We conclude that SLNB in anal cancer is technically feasible.
  • However, because of the occurrence of inguinal lymph node metastases after a tumor-negative SLNB, introduction of this procedure as standard of care in all patients with anal carcinoma should be done with caution to avoid undertreatment of patient who otherwise would benefit from inguinal radiotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):238-42 [2672386.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):255-8 [8345551.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):270-4 [9015169.001]
  • [Cites] Ann Surg Oncol. 1997 Mar;4(2):156-60 [9084853.001]
  • [Cites] World J Surg. 1997 Oct;21(8):788-92; discussion 793 [9327667.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):31-5 [16372147.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1511-6 [17009151.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Br J Radiol. 2009 Jan;82(973):41-8 [19095815.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Feb;53(1):3-8 [18337684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] ANZ J Surg. 2002 Sep;72(9):651-4 [12269917.001]
  • [Cites] Scand J Surg. 2002;91(4):336-8 [12558082.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1027-9; discussion 1030-1 [12907894.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1032-7 [12907896.001]
  • [Cites] Onkologie. 2003 Oct;26(5):456-60 [14605462.001]
  • [Cites] Cancer Radiother. 2003 Nov;7 Suppl 1:85s-90s [15124549.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):43-8 [6691550.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • (PMID = 20865825.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2941712
  •  go-up   go-down


57. Kawahara H, Watanabe K, Ushigome T, Noaki R, Kobayashi S, Yanaga K: Retrograde single stapling technique for laparoscopic ultralow anterior resection. Dig Surg; 2010;27(4):261-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the anal side of the tumor has been closed transanally, the distal line in the right lateral wall of the rectum is partially transected with laparoscopic coagulation shears (LCS).
  • After an anvil is placed in the proximal end of the colon over a purse-string suture, it is introduced to the anal canal transabdominally.
  • For the prevention of anastomotic leakage, a 24-french balloon catheter which decompresses the anastomosis is inserted through the anus.
  • [MeSH-major] Laparoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery. Surgical Stapling / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Anal Canal / surgery. Anastomosis, Surgical / methods. Anastomotic Leak. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Proctoscopy / methods. Risk Assessment. Sampling Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20668381.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


58. Rossitto M, Pantè S, Manfrè A, Ciccolo A: [Post-operative analgesia in case of ano-rectal diseases]. Ann Ital Chir; 2009 Nov-Dec;80(6):459-61; discussion 461
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-operative analgesia in case of ano-rectal diseases].
  • [Transliterated title] L'analgesia post-operatoria nel trattamento delle patologie ano-rettali.
  • BACKGROUND: The aim of the study was that to evaluate the post-operative pain in case of ano-rectal diseases wether treated by ketorolac, or buprenorphine or tramadol.
  • MATERIALS AND METHODS: The intensity of post-operative pain was evaluated in 60 patients with hemorrhoidal diseases, fistulae, abscesses and anal neoplasms, divided into three homogenous groups and treated with intramuscular ketorolac (Group I), transdermal buprenorphine (Group II) and tramadol in elastomeric pump (Group III).
  • CONCLUSIONS: Better compliance and lower operating costs have given the preference to the use of transdermal buprenorphine for the treatment of diseases of the post-operative pain in the diseases of the anal canal.
  • [MeSH-minor] Adolescent. Adult. Aged. Analgesics, Opioid / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Anus Diseases / surgery. Buprenorphine / therapeutic use. Female. Humans. Ketorolac / therapeutic use. Male. Middle Aged. Tramadol / therapeutic use. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476679.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 39J1LGJ30J / Tramadol; 40D3SCR4GZ / Buprenorphine; YZI5105V0L / Ketorolac
  •  go-up   go-down


59. Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P: Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma. Chin Med J (Engl); 2010 Mar 5;123(5):585-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma.
  • BACKGROUND: Anorectal malignant melanoma was a rare disease with extremely poor prognosis.
  • The aim of this study was to explore the clinical characteristic, diagnosis and treatment strategies of anorectal malignant melanoma.
  • METHODS: The data of 57 patients with anorectal malignant melanoma was collected and retrospectively analyzed.
  • RESULTS: Rectal bleeding and anal mass were found to be common symptoms of anorectal malignant melanoma.
  • The preoperative diagnosis rate of anorectal malignant melanoma was 48.6%.
  • The 3-year survival rates of stage I and II patients were 63.0% and 16.7% respectively (P = 0.000), and the 5-year survival rates were 33.3% and 11.1% (P = 0.001), which both had significant statistic differences.
  • CONCLUSIONS: This study identified no survival advantage to abdominoperineal resection in treatment of anorectal malignant melanoma, and we propose that wide local excision could be considered as the initial treatment of choice.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367986.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Mistrangelo M, Pelosi E, Bellò M, Castellano I, Cassoni P, Ricardi U, Munoz F, Racca P, Contu V, Beltramo G, Morino M, Mussa A: Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
  • BACKGROUND: Inguinal lymph node metastases in patients with anal cancer are an independent prognostic factor for local failure and overall mortality.
  • CONCLUSIONS: In this series of patients with anal cancer, inguinal sentinel node biopsy was superior to PET-CT for staging inguinal lymph nodes.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Positron-Emission Tomography / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / methods. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Inguinal Canal. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


61. Rogers LJ, Howard B, Van Wijk L, Wei W, Dehaeck K, Soeters R, Denny LA: Chemoradiation in advanced vulval carcinoma. Int J Gynecol Cancer; 2009 May;19(4):745-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Vulval carcinoma is uncommon, affecting approximately 2 per 100,000 women annually.
  • Advanced vulval carcinomas involve midline structures (such as clitoris, urethra, or anus) and/or adjacent pelvic organs or bone, and adequate excision may require urinary diversion, colostomy, or pelvic exenteration.
  • Less morbid and less mutilating therapeutic alternatives have been investigated, particularly chemoradiation, which has shown success in the management of anal carcinomas.
  • Other prognostic factors for survival were performance status and tumor stage.
  • Survival was improved in women who responded partially but had residual disease surgically excised.
  • Performance status, age, and tumor stage were also associated with survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509582.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


62. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • There was not a significant difference in survival by hospital type or year of diagnosis.
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Yakovlev AE, Ellias Y: Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clin Med Res; 2008 Dec;6(3-4):103-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1 reports a 51-year-old male with burning pain at the left groin site of inguinal metastases, post-surgical and intraoperative radiation therapy for treatment of squamous cell carcinoma of the anus.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Electric Stimulation Therapy. Neuralgia / therapy. Spinal Cord. Spinal Cord Neoplasms / therapy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Palliative Care

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hosp J. 1999;14(2):35-47 [10624231.001]
  • [Cites] J Pain Symptom Manage. 2004 Jan;27(1):72-8 [14711471.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3 Suppl Spine):254-67 [15029914.001]
  • [Cites] Science. 1965 Nov 19;150(3699):971-9 [5320816.001]
  • [Cites] Surg Neurol. 1977 Apr;7(4):192 [300508.001]
  • [Cites] J Pain Symptom Manage. 1990 Feb;5(1):27-32 [2324558.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Jun 1;21(11):1344-50; discussion 1351 [8725927.001]
  • [Cites] Surg Neurol. 1996 Oct;46(4):363-9 [8876718.001]
  • [Cites] Lancet. 1996 Dec 21-28;348(9043):1698-701 [8973433.001]
  • [Cites] IEEE Trans Rehabil Eng. 1998 Sep;6(3):277-85 [9749905.001]
  • [Cites] Am Heart J. 1998 Dec;136(6):1114-20 [9842028.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):402-8 [10070441.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 May;15(2):138-45 [16643261.001]
  • [Cites] Pain Pract. 2007 Dec;7(4):345-7 [17986168.001]
  • (PMID = 19325172.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2670524
  •  go-up   go-down


64. Pocard M, Sabourin JC: [Sentinel lymph node biopsy in gastro-intestinal surgery: facts and future implications]. J Chir (Paris); 2008 Dec;145 Spec no. 4:12S17-12S20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • This finding has been noted in 10-15% of cases.
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Anus Neoplasms / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures. Humans. Neoplasm Staging. Prognosis. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194353.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 99
  •  go-up   go-down


65. Walts AE, Bose S: BD ProEx C immunostaining in extramammary Paget's disease and perineal melanoma. Mod Pathol; 2009 Feb;22(2):246-51
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BD ProEx C immunostaining in extramammary Paget's disease and perineal melanoma.
  • The differential diagnosis of perineal biopsies can include squamous intraepithelial lesions, extramammary Paget's disease, and melanoma.
  • Immunostaining for ProEx C has been validated in cervical cytology and positive staining has also been shown to be strongly associated with human papilloma virus (HPV)-induced cervical and anal intraepithelial neoplasia in biopsies.
  • We observed positive staining for ProEx C in Paget cells in all of 26 cases of Paget's disease irrespective of tissue site (extramammary, mammary) and in melanoma cells in all of 12 cases of primary perineal melanoma with immunostaining in >50% of malignant cells in 73% of Paget disease cases and 43% of perineal melanoma cases.
  • [MeSH-major] Antigens, Neoplasm / analysis. Anus Neoplasms / enzymology. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Melanoma / enzymology. Nuclear Proteins / analysis. Paget Disease, Extramammary / enzymology. Perineum / pathology. Reagent Kits, Diagnostic. Vaginal Neoplasms / enzymology. Vulvar Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Biopsy. DNA, Viral / isolation & purification. Diagnosis, Differential. Female. Humans. Immunoassay. In Situ Hybridization. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Mucous Membrane / enzymology. Mucous Membrane / pathology. Mucous Membrane / virology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931649.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Cycle Proteins; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


66. Vella JE, Taibjee SM, Sanders DS, Stellakis M, Carr RA: Fibroadenoma of the anogenital region. J Clin Pathol; 2008 Jul;61(7):871-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenoma of the anogenital region is a rare tumour histologically similar to fibroadenoma of the breast.
  • [MeSH-major] Anus Neoplasms / pathology. Fibroadenoma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Neoplasm Proteins / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587019.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


67. Mai SK, Welzel G, Haegele V, Wenz F: The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. Radiat Oncol; 2007;2:30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer.
  • We evaluated the effect of smoking during radiochemotherapy on the outcome for patients with anal cancer.
  • METHODS: Sixty-eight patients (34 smokers, 34 non-smokers) treated by radiochemotherapy for anal cancer were analysed.
  • The effect of smoking during radiochemotherapy and other risk factors (gender, T- and N category, tumor site, dose, therapy protocol) on disease-specific survival (DSS), local control (LC) and colostomy free survival (CFS) was evaluated.
  • CONCLUSION: Even though our evaluation reached statistical significance only in univariate analysis, we suggest, that the role of smoking during radiochemotherapy for anal cancer should not be ignored.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Smoking / adverse effects
  • [MeSH-minor] Adult. Aged. Colostomy / statistics & numerical data. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Retrospective Studies. Risk Factors. Sex Characteristics. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Carcinogenesis. 1993 Feb;14(2):329-32 [8382117.001]
  • [Cites] FASEB J. 1993 Aug;7(11):1045-51 [8370474.001]
  • [Cites] Rev Med Interne. 1993 May;14(5):340-9 [8235150.001]
  • [Cites] J Cutan Med Surg. 2001 Jul-Aug;5(4):323-8 [11907844.001]
  • [Cites] Head Neck. 2002 Dec;24(12):1031-7 [12454940.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Mutat Res. 2004 Jun 13;560(2):167-72 [15157654.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] JAMA. 1980 Nov 14;244(19):2175-9 [6252357.001]
  • [Cites] Int J Cancer. 1981 Aug 15;28(2):153-6 [7319670.001]
  • [Cites] J Natl Cancer Inst. 1982 Mar;68(3):395-9 [6950166.001]
  • [Cites] Can Med Assoc J. 1982 Oct 15;127(8):727-9 [7139487.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] Clin Exp Immunol. 1985 Aug;61(2):459-66 [2931227.001]
  • [Cites] Cancer. 1989 May 15;63(10):2060-5 [2702575.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4024-9 [2736543.001]
  • [Cites] Int J Colorectal Dis. 1989 Dec;4(4):234-43 [2614221.001]
  • [Cites] FASEB J. 1994 Jun;8(9):654-60 [8005393.001]
  • [Cites] Gynecol Obstet Invest. 1995;39(1):34-8 [7890250.001]
  • [Cites] Gynecol Obstet Invest. 1996;41(4):253-9 [8793496.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • (PMID = 17711570.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2078591
  •  go-up   go-down


68. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist; 2007 May;12(5):524-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: an overview.
  • Anal cancer is a rare tumor with an incidence that has been rising over the last 25 years.
  • The disease was once thought to develop as a result of chronic irritation, but it is now known that this is not the case.
  • HIV infection is also associated with anal cancer; there is a higher incidence in HIV-positive patients but the direct relationship between HIV and anal cancer has been difficult to separate from the prevalence of HPV in this population.
  • HIV infection is also associated with anal cancer; there are increasing numbers of HIV-positive patients being diagnosed with the disease.
  • Treatment of anal cancer prior to the 1970s involved abdominoperineal resection, but the standard of care is now concurrent chemoradiation therapy, with surgery reserved for those patients with residual disease.
  • We present a case of anal cancer followed by a general discussion of both risk factors and treatment.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. HIV Infections / complications. Humans. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / complications. Risk Factors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522240.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


69. Zibly Z, Haik J, Khaikin M, Barshack I, Zmora O: Perianal Paget's disease. J Cutan Med Surg; 2006 Jul-Aug;10(4):197-200
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal Paget's disease.
  • BACKGROUND: Perianal Paget's disease is an uncommon intraepithelial neoplasm that involves areas affluent with apocrine glands, most frequently in the female external genitalia, but may also affect the perianal region.
  • OBJECTIVE: We present the pathologic and clinical management of a case of Paget's disease involving the perianal region, in which diagnosis was delayed for 8 years.
  • CONCLUSIONS: The importance of a high index of suspicion for early diagnosis is emphasized, which should be followed by aggressive surgical treatment with wide excision and local reconstruction.
  • [MeSH-major] Anus Neoplasms / diagnosis. Paget Disease, Extramammary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234119.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Podnos YD, Tsai NC, Smith D, Ellenhorn JD: Factors affecting survival in patients with anal melanoma. Am Surg; 2006 Oct;72(10):917-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting survival in patients with anal melanoma.
  • Anal melanoma is an aggressive tumor with a predilection for early infiltration and distant spread, resulting in poor overall survival.
  • Because anal melanoma is rare, only small case series are reported in the literature, making it difficult to draw conclusions about optimal treatment and outcome.
  • The Surveillance, Epidemiology, and End Results database was used to identify patients with anal melanomas from 1973 to 2001.
  • In addition to demographics, disease extent at presentation, treatment administered, overall survival, and survival by decade of diagnosis were collected.
  • A total of 126 patients with a mean age of 69.2 years was diagnosed with anal melanoma.
  • Sixty-one per cent were female.
  • Median survival was 10 months for those with distant disease, 13 months for patients with regional spread, and 34 months for patients with local disease (P = 0.0001).
  • Five-year survival was 32 per cent, 17 per cent, and 0 per cent for patients presenting with local, regional, and distant disease, respectively (P = 0.0001).
  • Neither age at diagnosis, operation performed, nor use of radiation significantly affected survival.
  • Anal melanoma remains an uncommon but lethal disease.
  • Extent of disease correlates with overall survival.
  • [MeSH-major] Anus Neoplasms / mortality. Melanoma / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. SEER Program / statistics & numerical data. Sex Factors. Survival Rate. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058735.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Chen LS, Li TY, Cao YF, Liang JL, Zhang S, Tang WZ, Tang ZJ, Gao F: [Expression of P33ING1, P53 and their relationship with apoptosis in anal canal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul;9(4):338-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P33ING1, P53 and their relationship with apoptosis in anal canal carcinoma].
  • OBJECTIVE: To explore the expressions of P33ING1, P53 and their relationships with apoptosis in anal canal carcinoma (ACC).
  • METHODS: The expressions of P33ING1, P53 proteins were measured by immunohistochemistry method (SP method), and apoptosis was detected in 42 cases with ACC, 36 cases with anal canal adenoma (ACA) or anal canal papilloma (ACP), and 40 cases with paraanal inflammatory mass(PAIM).
  • RESULTS: The positive expression rates of P33ING1 and P53 proteins were 40.5% (17/42), 97.2% (35/36) and 97.5% (39/40), 50.0% (21/42), 22.2% (8/36) and 27.5% (11/40) respectively, and the average apoptosis indexes(AI) were (10.27+/- 1.23) per thousand, (42.75+/- 0.98) per thousand and (42.67+/- 1.04) per thousand respectively in ACC, ACA or ACP and PAIM.
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Nuclear Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886119.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ING1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


72. Hung AY, Canning CA, Patel KM, Holland JM, Kachnic LA: Radiation therapy for gastrointestinal cancer. Hematol Oncol Clin North Am; 2006 Apr;20(2):287-320
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Esophageal Neoplasms / radiotherapy. Gastrointestinal Neoplasms / radiotherapy
  • [MeSH-minor] Anus Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Colonic Neoplasms / radiotherapy. Combined Modality Therapy. Humans. Liver Neoplasms / radiotherapy. Neoplasm Staging. Pancreatic Neoplasms / radiotherapy. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730296.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 149
  •  go-up   go-down


73. Bamba Y, Itabashi M, Hirosawa T, Ogawa S, Seshimo A, Shirotani N, Kameoka S: Follow-up and recurrence of T1 colorectal cancer. Int Surg; 2006 Jan-Feb;91(1):12-6
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disease recurrence occurred in eight (3%) of these cases.
  • We performed three local resections per anus and five bowel resections with lymph node dissection.
  • [MeSH-major] Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706096.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


74. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Metastatic disease spread to lymph nodes, viscera and bone was recorded.
  • In all, 7 patients with recurrent disease underwent surgery and subsequent histological correlation was performed.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • Recurrent lymph node disease involved perirectal, presacral and internal iliac nodes more commonly than did primary lymph node disease.
  • MR has a role in the preoperative evaluation and surgical planning of cases of recurrent disease following radiotherapy.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Sato H, Koh PK, Bartolo DC: Management of anal canal cancer. Dis Colon Rectum; 2005 Jun;48(6):1301-15
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal canal cancer.
  • PURPOSE: Chemoradiotherapy has replaced radical surgery as the initial treatment of choice for anal canal cancer.
  • The roles of these therapeutic modalities are discussed and recommendations on management of anal canal cancer are made based on currently available evidence.
  • METHODS: Literature on management of anal canal cancer from January 1970 to July 2003 obtained via MEDLINE was reviewed.
  • Reports on anal margin cancers were excluded.
  • In larger tumors, the addition of mitomycin C to radiotherapy and 5-fluorouracil improves local control, colostomy-free, and disease-free survival but is associated with more acute hematologic toxicity.
  • Chemoradiotherapy, including Cisplatin and 5-fluorouracil, appeared to be equal or superior to surgery as salvage therapy in patients with residual disease six weeks after initial nonsurgical treatment.
  • Few studies addressed the treatment of metastatic disease, which remains a major cause of mortality.
  • [MeSH-major] Anus Neoplasms / therapy
  • [MeSH-minor] Brachytherapy. Chemotherapy, Adjuvant. Digestive System Surgical Procedures. Dose Fractionation. Humans. Lymphatic Metastasis. Neoplasm Staging. Radiotherapy, High-Energy. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793642.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 116
  •  go-up   go-down


76. de Parades V, Bauer P, Benbunan JL, Bouillet T, Cottu PH, Cuenod CA, Durdux C, Fléjou JF, Atienza P: [Initial pretherapeutic assessment of anal epidermoid carcinoma]. Gastroenterol Clin Biol; 2007 Feb;31(2):157-65
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Initial pretherapeutic assessment of anal epidermoid carcinoma].
  • [Transliterated title] Bilan préthérapeutique initial du carcinome épidermoïde invasif de l'anus.
  • Anal epidermoid carcinoma is a rare malignant tumor, comprising less than 5% of all carcinomas of the colon, rectum, and anus.
  • In addition, magnetic resonance imaging, positron emission tomography scanning and inguinal sentinel lymph node procedure should play a role in a more selective approach in patients with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Diagnostic Imaging. Humans. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347624.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 96
  •  go-up   go-down


77. Poggi MM, Suh WW, Saltz L, Konski AA, Mohiuddin M, Herman J, Johnstone PA: ACR Appropriateness Criteria on treatment of anal cancer. J Am Coll Radiol; 2007 Jul;4(7):448-56
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR Appropriateness Criteria on treatment of anal cancer.
  • Anal cancer is a relatively rare neoplasm, accounting for roughly 4,500 cases per year.
  • The evolution of the definitive treatment of anal cancer from a surgical to a nonsurgical approach, however, has been viewed as a model disease site in a larger paradigm shift in medicine.
  • Organ preservation, in this case a functional anal sphincter, and durable cure are obtainable goals.
  • To this end, anal cancer is a disease best treated primarily with chemoradiation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Mitomycin / therapeutic use. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601586.001).
  • [ISSN] 1558-349X
  • [Journal-full-title] Journal of the American College of Radiology : JACR
  • [ISO-abbreviation] J Am Coll Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


78. Zucchini C, Concu M, Martini F, Morelli C, Salfi N, Carinci P, Tognon M, Caramelli E: FHIT oncosuppressor gene expression profile in human anal cancers. Int J Biol Markers; 2007 Jan-Mar;22(1):39-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FHIT oncosuppressor gene expression profile in human anal cancers.
  • The FHIT gene, a member of the histidine triad gene family, is a tumor suppressor gene exhibiting deletions in the majority of human cancers.
  • Little is known about the molecular mechanisms involved in malignant transformation of the lining cells of the anus.
  • FHIT expression was comparatively analyzed at the mRNA level, by RT-PCR, in squamous anal cancers, normal anal tissue and peripheral blood samples. cDNA analyses showed variability in FHIT transcripts, without apparent effects on the predicted amino acid sequence.
  • Our data indicate that the FHIT mRNA detected in anal cancers and in normal samples is heterogeneous.
  • Immunohistochemical data suggest that the Fhit protein is expressed only in a fraction of the tumor cells, while it is strongly expressed in the epithelial cells of glands of the normal anal mucosa.
  • The absence or poor expression of the Fhit protein in anal cancers suggests a role for this tumor suppressor gene product, as a risk factor, in the onset of this human cancer, as reported before for other human gastrointestinal tumors.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Anus Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393360.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


79. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • The average age at diagnosis was 63.4 years.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


80. Tsai WP, Shieh SJ, Lin BW: Extensive perineal and pelvic defects reconstructed simultaneously using bilateral pedicled gracilis and rectus abdominis muscle flaps after en-bloc excision of locally invasive perineal mucinous adenocarcinoma 1. Scand J Plast Reconstr Surg Hand Surg; 2009;43(5):286-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of successful simultaneous reconstruction of pelvic and perineal defects using bilateral pedicled gracilis and inferiorly based rectus abdominis muscle flaps after en-bloc excision of the tumour and abdominoperineal resection of locally advanced invasive perineal mucinous adenocarcinoma originating from a chronic anal fistula.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863433.001).
  • [ISSN] 1651-2073
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Gormley RH, Kovarik CL: Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep; 2009 Aug;6(3):130-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatologic human papillomavirus (HPV) infection in HIV patients manifests as both anogenital and nongenital skin disease.
  • Anogenital HPV-related disease includes benign condyloma acuminata, the most common cutaneous manifestation of genital HPV infection; intermediate malignancy or premalignant conditions including giant condyloma acuminata (also called Buschke-Loewenstein tumor), anal intraepithelial neoplasia, penile intraepithelial neoplasia, and vaginal or vulvar intraepithelial neoplasia; and frankly malignant disease including Bowen's disease and invasive anal, penile, or vulvar carcinoma.
  • Cutaneous HPV-related disease in nongenital skin is also increased in HIV-positive patients, in the form of benign common warts, epidermodysplasia verruciformis-like skin lesions, and nonmelanoma skin cancers.
  • This review and update addresses the above listed dermatologic manifestations of HPV disease in HIV-infected individuals, with an emphasis on new findings and published data from 2006 to 2008.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Carcinoma in Situ / etiology. Carcinoma in Situ / physiopathology. Humans. Papillomavirus Vaccines / therapeutic use. Skin Neoplasms / etiology. Skin Neoplasms / physiopathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589298.001).
  • [ISSN] 1548-3576
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 69
  •  go-up   go-down


82. Kreuter A, Wieland U: Human papillomavirus-associated diseases in HIV-infected men who have sex with men. Curr Opin Infect Dis; 2009 Apr;22(2):109-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review summarizes recent data on papillomavirus-induced anal intraepithelial neoplasia and anal cancer in these patients.
  • RECENT FINDINGS: The incidence of anal intraepithelial neoplasia rises in HIV-positive men who have sex with men despite the introduction of highly active antiretroviral therapy.
  • Increasing evidence indicates that high-grade lesions can progress to anal cancer over time.
  • Anal cytology has been recommended as the primary screening tool for anal dysplasia in the at-risk population.
  • Anal cancer has become one of the most common non-AIDS-defining tumors in HIV-infected individuals.
  • In the era of highly active antiretroviral therapy, the outcome of combined chemoradiotherapy in HIV-positive individuals with anal cancer is similar to that in HIV-negative persons.
  • SUMMARY: Diagnostic and therapeutic guidelines should be implemented for at-risk populations for anal dysplasia/anal cancer, such as HIV-positive men who have sex with men.
  • More study is required to get better insights into the natural history of penile and oral HPV-associated benign and malignant lesions.
  • [MeSH-major] Anus Neoplasms / epidemiology. Anus Neoplasms / virology. HIV Infections / complications. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology
  • [MeSH-minor] Homosexuality, Male. Humans. Incidence. Male. Mouth Neoplasms / epidemiology. Mouth Neoplasms / virology. Penile Neoplasms / epidemiology. Penile Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276878.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


83. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • The tumour-stage group was changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged).
  • Sensitivity for nodal regional disease by FDG-PET and CIm was 89% and 62%, respectively.
  • The estimated 5-year PFS for FDG-PET and CIm staged N2-3 disease was 70% (95% CI: 42.8-87.9%) and 55.3% (95% CI: 23.3-83.4%), respectively.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


84. David AW, Perakath B: Management of anorectal melanomas: a 10-year review. Trop Gastroenterol; 2007 Apr-Jun;28(2):76-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anorectal melanoma (AM) is a rare tumour with poor prognosis.
  • Patients were followed up to assess disease free and overall survival according to the stage of disease and the surgical procedure performed.
  • At presentation 4 (23%) had metastatic and 1 (6%) had inoperable disease.
  • 82% of these patients were followed up for a mean duration of 8 months (range 3-30 months) and their overall and disease free survival compared.
  • The stage specific disease free and overall survival for patients who underwent APER was 8 months and 13 months for stage I and 7 months and 10 months for stage II respectively.
  • The disease free survival and overall survival for patients who underwent WLE, both for stage I disease, was 10 months and 27 months respectively.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050846.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 13
  •  go-up   go-down


85. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • RESULTS: The first patient had a good symptomatic response to the chemoradiation but unfortunately died of recurrent disease following surgery.
  • CONCLUSION: Pre-operative chemoradiation has proved to be useful in management for histologically proven benign BLT
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Condylomata Acuminata / therapy. Neoadjuvant Therapy. Perineum / pathology. Perineum / surgery. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Salerno G, Sinnatamby C, Branagan G, Daniels IR, Heald RJ, Moran BJ: Defining the rectum: surgically, radiologically and anatomically. Colorectal Dis; 2006 Sep;8 Suppl 3:5-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The terminology used in relation to the rectum varies considerably, added to this there is the subjective nature of clinical assessment and variability in the anatomy of the rectum and anus.
  • [MeSH-major] Anal Canal / anatomy & histology. Colectomy / methods. Colorectal Neoplasms / surgery. Rectum / anatomy & histology. Terminology as Topic
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Mesentery / anatomy & histology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813584.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  •  go-up   go-down


87. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC: Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol; 2006 Jan;36(1):55-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m(2), continuous infusion for 5 days q4 weeks.
  • In conclusion, we report that encephalopathy can develop even with the dose of 5-FU lower than ever reported, and it should be considered as a differential diagnosis for proper management.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / pathology. Cisplatin / administration & dosage. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Hyperammonemia / complications. Infusions, Intravenous. Male. Neoplasm Invasiveness

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436463.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Hwang HJ, Bestani C, Jiménez R, Masciángioli G, Gutiérrez A, Cartelli C, Rafailovici L, Barugel M, Rodríguez G, Méndez G: [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital]. Acta Gastroenterol Latinoam; 2005;35(2):94-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].
  • [Transliterated title] El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital.
  • Anal cancers compromise only 1.5% of all digestive tumors.
  • OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with squamous cell carcinoma of the anal canal (SCCAC) treated by the Oncology Section in 20 years.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127985.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


89. Trautmann TG, Zuger JH: Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol; 2005 Jul-Aug;7(4):309-13
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal.
  • PURPOSE: In recent years, combined modality therapy (CMT) with chemotherapy and radiation has replaced surgery as the preferred treatment for cancer of the anal canal.
  • Clinical staging with computed tomography (CT) scan alone may underestimate the extent of disease.
  • PATIENTS AND METHODS: From September 1999 to August 2002, 21 patients with cancer of the anal canal were studied prospectively.
  • In another patient, PET confirmed the presence of suspected M(1) disease in the liver.
  • CONCLUSIONS: FDG-PET, in conjunction with CT scanning, provides additional staging information in cancer of the anal canal.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Anus Neoplasms / pathology. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028002.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Samalavicius NE, Rudinskaite G, Pavalkis D, Latkauskas T, Kaselis N, Sidlauskas Z, Sniuolis P, Poskus T, Kvedaras V, Strupas K, Poskus E: [Laparoscopic surgery for malignancies of the colon, rectum, and anus in Lithuania in 2008]. Medicina (Kaunas); 2009;45(6):447-51
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery for malignancies of the colon, rectum, and anus in Lithuania in 2008].
  • THE OBJECTIVE OF THIS STUDY: was to analyze data on laparoscopic surgery for malignant diseases of the colon, rectum, and anus in Lithuania during the period of January 1, 2005, to February 15, 2008.
  • MATERIAL AND METHODS: During the above-mentioned period in Lithuania, 130 laparoscopic surgeries for malignancies of colon, rectum, and anus were performed in seven different hospitals.
  • Twenty-seven (20.8%) patients had stage I, 45 (34.6%) stage II, 45 (34.6%) stage III, and 13 (10%) stage IV disease.
  • CONCLUSIONS: Laparoscopic surgery for malignant diseases of the colon, rectum, and anus is dominating among laparoscopic surgeries for colorectum.
  • To evaluate disease relapse and outcomes, observation time is not sufficient yet.
  • [MeSH-major] Anus Neoplasms / surgery. Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Colon / pathology. Female. Humans. Length of Stay. Lithuania. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Staging. Postoperative Complications. Randomized Controlled Trials as Topic. Rectum / pathology. Reoperation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605964.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


91. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA: Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1064-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
  • PURPOSE: Intensity-modulated radiation treatment (IMRT) is increasingly used in the treatment of squamous cell carcinoma of the anal canal (SCCAC).
  • All patients received radiation; the median primary tumor dose was 45 Gy.
  • All patients with common iliac failure had cT3 or N+ disease.
  • In patients with advanced tumor or nodal stage, common iliac nodes should also be included in the CTV.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Tumor Burden
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Irradiation. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiotherapy Dosage. Treatment Failure

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20350793.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) were drawn on CT and on PET/CT fused images.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


93. Schizas AM, Williams AB, Meenan J: Endosonographic staging of lower intestinal malignancy. Best Pract Res Clin Gastroenterol; 2009;23(5):663-70
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EUS is also of benefit in the assessment of anal pathology though here, accurate correlation with histology has not been firmly established.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Colonic Neoplasms / ultrasonography. Endoscopy, Gastrointestinal. Endosonography. Rectal Neoplasms / ultrasonography
  • [MeSH-minor] Humans. Neoplasm Staging. Predictive Value of Tests. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744631.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 64
  •  go-up   go-down


94. Orlando G, Beretta R, Fasolo MM, Amendola A, Bianchi S, Mazza F, Rizzardini G, Tanzi E: Anal HPV genotypes and related displasic lesions in Italian and foreign born high-risk males. Vaccine; 2009 May 29;27 Suppl 1:A24-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal HPV genotypes and related displasic lesions in Italian and foreign born high-risk males.
  • Anal intraepithelial neoplasia and anal cancer are closely related to infection from high-risk Human Papilloma Virus (HPV) genotypes.
  • Since HPVs involved in disease progression are reported to vary by geographical regions, this study focuses on HPV genotypes spectrum in 289 males attending a Sexual Transmitted Diseases (STD) unit according to their nationality.
  • Anal cytology, Digene Hybrid Capture Assay (HC2) and HPV genotyping were evaluated in 226 Italian (IT) and 63 foreign born (FB) subjects, recruited between January 2003 and December 2006.
  • FB people were younger (median 32y-IQR 27-35 vs 36y-IQR 31-43, respectively; Mann-Whitney test p<0.0001) and had a higher rate of abnormal results (>or=atypical squamous cells of undetermined significance (ASCUS)) on anal cytology (95.0% vs 84.04%) (p=0.032; OR 3.61; 95% CI 1.04-1.23).
  • HPV-16 is by far the most common genotype found in anal cytological samples independently from nationality while differences in distribution of other HPV genotypes were observed.
  • The relative contribution of each HPV genotype in the development of pre-neoplastic disease to an early age in the FB group cannot be argued by this study and more extensive epidemiological evaluations are needed to define the influence of each genotype and the association with the most prevalent high-risk HPVs on cytological intraepithelial lesions development.
  • [MeSH-major] Anus Neoplasms / virology. Papillomaviridae / genetics. Papillomavirus Infections / pathology
  • [MeSH-minor] Adult. Anal Canal / virology. Cross-Sectional Studies. DNA, Viral / genetics. Genotype. HIV Infections / complications. HIV Infections / virology. Humans. Italy / epidemiology. Male. Prevalence. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480957.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


95. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • Persistent disease occurred in 46 patients (18.7 percent), requiring planned staged therapy; 10 required surgery.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Immunocompromised Host. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Complications. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Mitsuya J, Hara H, Ito K, Ishii N, Hashimoto T, Terui T: Metastatic ovarian carcinoma-associated subepidermal blistering disease with autoantibodies to both the p200 dermal antigen and the gamma 2 subunit of laminin 5 showing unusual clinical features. Br J Dermatol; 2008 Jun;158(6):1354-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ovarian carcinoma-associated subepidermal blistering disease with autoantibodies to both the p200 dermal antigen and the gamma 2 subunit of laminin 5 showing unusual clinical features.
  • Anti-p200 pemphigoid is an autoimmune subepidermal blistering disease characterized by autoantibodies to an unknown 200-kDa acidic noncollagenous glycoprotein of the lower lamina lucida, whereas antilaminin 5 mucous membrane pemphigoid is characterized by autoantibodies to a major basement membrane extracellular matrix, laminin 5.
  • We report a 64-year-old Japanese woman with a subepidermal blistering disease associated with lymph node metastasis of ovarian clear cell carcinoma 10 years after its surgical treatment.
  • Clinical features showed severe blisters and erosions on multiple mucous membranes (i.e. lip, oral cavity, nose, eye, genitalia and anus) and on both the periungual and subungual regions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Antigens, Neoplasm / immunology. Autoantibodies / immunology. Blister / immunology. Epidermolysis Bullosa Acquisita / diagnosis. Laminin / immunology. Ovarian Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294311.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Immunoglobulin G; 0 / LAMC2 protein, human; 0 / Laminin; 0 / antigen p200
  •  go-up   go-down


97. Retamozo-Palacios M, de Sousa JB, Santos JB: [Anorectal lesions in HIV-positive patients using highly active antiretroviral therapy]. Rev Soc Bras Med Trop; 2007 May-Jun;40(3):286-9
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lesões anorretais em pacientes HIV positivos usuários de terapia anti-retroviral de alta efetividade.
  • Highly active anti-retroviral therapy (HAART) has little influence on the progression of anal neoplasms.
  • Around 71% of the patients said they practiced anal intercourse.
  • The prevalence of anorectal lesions was 36.4%, and condyloma acuminata and anal fissure were the most frequent of these.


98. Holm T, Ljung A, Häggmark T, Jurell G, Lagergren J: Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg; 2007 Feb;94(2):232-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraoperative tumour perforation, positive tumour margins, wound complications and local recurrence are frequent difficulties with conventional abdominoperineal resection (APR) for rectal cancer.
  • METHODS: The principles of operation are that the mesorectum is not dissected off the levator muscles, the perineal dissection is done in the prone position and the levator muscles are resected en bloc with the anus and lower rectum.
  • [MeSH-major] Pelvic Floor / surgery. Perineum / surgery. Rectal Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 British Journal of Surgery Society Ltd.
  • (PMID = 17143848.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • Mean age at diagnosis was 59 (range: 41-83) years.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Nilsson PJ, Rubio C, Lenander C, Auer G, Glimelius B: Tumour budding detected by laminin-5 {gamma}2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer. Ann Oncol; 2005 Jun;16(6):893-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour budding detected by laminin-5 {gamma}2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer.
  • BACKGROUND: Markers for guidance with regard to individual prognosis and treatment planning are sought in epidermoid anal cancer.
  • This study assessed the prognostic and predictive value of tumour budding.
  • Immunohistochemistry with a monoclonal antibody for the gamma2 chain of laminin-5 was used to detect tumour budding (defined as dissociated single cancer cells or clusters of up to five cells).
  • RESULTS: Tumour budding was detected in 104 (50%) of the 209 samples.
  • No significant correlation was found between tumour budding and clinicopathological characteristics.
  • Patients with tumour budding had a statistically significantly better 5-year overall survival rate compared with patients lacking tumour budding (74% versus 64%, P <0.05).
  • Albeit not statistically significant, other outcome variables such as tumour-specific survival, recurrence after initial complete response and rate of distant metastases, were all in favour of patients with tumour budding.
  • Multivariate analysis reveals tumour budding as an independent positive prognostic factor.
  • CONCLUSIONS: Tumour budding detected by laminin-5 immunohistochemistry may be of prognostic value in the treatment of epidermoid anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821121.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down






Advertisement